Alaunos Therapeutics, Inc.
TCRT
$2.63
-$0.05-1.87%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 80.00% | -60.00% | -99.79% | -99.79% | -99.83% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 80.00% | -60.00% | -99.79% | -99.79% | -99.83% |
| Cost of Revenue | -97.77% | -92.51% | -78.43% | -57.76% | -27.70% |
| Gross Profit | 97.82% | 92.54% | 75.26% | 51.78% | 16.95% |
| SG&A Expenses | -63.51% | -52.49% | -30.65% | -16.68% | -7.02% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -83.08% | -76.18% | -61.53% | -43.25% | -20.08% |
| Operating Income | 83.11% | 76.19% | 58.05% | 38.29% | 12.96% |
| Income Before Tax | 86.68% | 67.68% | 48.06% | 29.52% | 6.86% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 86.68% | 67.68% | 48.06% | 29.52% | 6.86% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 86.68% | 67.68% | 48.06% | 29.52% | 6.86% |
| EBIT | 83.11% | 76.19% | 58.05% | 38.29% | 12.96% |
| EBITDA | 81.63% | 74.73% | 57.22% | 38.01% | 12.67% |
| EPS Basic | 86.70% | 68.32% | 50.41% | 34.48% | 15.76% |
| Normalized Basic EPS | 84.08% | 78.41% | 63.71% | 45.20% | 25.03% |
| EPS Diluted | 86.70% | 68.92% | 51.32% | 37.00% | 18.93% |
| Normalized Diluted EPS | 84.08% | 78.41% | 63.71% | 45.20% | 25.03% |
| Average Basic Shares Outstanding | 0.11% | 1.89% | 4.64% | 7.51% | 10.51% |
| Average Diluted Shares Outstanding | 0.11% | 1.89% | 4.64% | 7.51% | 10.51% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |